Market Research Logo

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Graft Versus Host Disease (GVHD) Overview
Therapeutics Development
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes
Graft Versus Host Disease (GVHD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Graft Versus Host Disease (GVHD) - Products under Development by Companies
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
AbbVie Inc.
AbGenomics International, Inc.
Actelion Ltd
Adienne Pharma & Biotech
Alexion Pharmaceuticals, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
Biogen, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Cell2B S.A.
CytoDyn Inc.
Dr. Falk Pharma GmbH
Enlivex Therapeutics Ltd
Escape Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Generon (Shanghai) Corporation Ltd.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
ImmuNext, Inc.
Immunomedics, Inc.
Jazz Pharmaceuticals Plc
Kadmon Corporation, LLC
Kamada Ltd.
Kiadis Pharma B.V.
Kymab Limited
MacroGenics, Inc.
Mesoblast Limited
Millennium Pharmaceuticals, Inc.
MSM Protein Technologies, Inc.
Neopharm Ltd.
Novartis AG
Omni Bio Pharmaceutical Inc.
Pharmicell Co., Ltd.
R-Tech Ueno, Ltd.
REGiMMUNE Corporation
Rigel Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Seattle Genetics, Inc.
Sigmoid Pharma Limited
Spherium Biomed S.L.
Targazyme, Inc.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Xenikos B.V.
Graft Versus Host Disease (GVHD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
AbGn-168H - Drug Profile
aldesleukin - Drug Profile
Alecmestencel-L - Drug Profile
Alpha-1 Antitrypsin - Drug Profile
alpha-1 proteinase inhibitor (human) - Drug Profile
ALXN-1007 - Drug Profile
anti-thymocyte globulin (rabbit) - Drug Profile
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
ApoCell - Drug Profile
ATIR-101 - Drug Profile
BCT-100 - Drug Profile
begelomab - Drug Profile
Biologics for Graft Versus Host Disease - Drug Profile
bortezomib - Drug Profile
BPX-501 - Drug Profile
brentuximab vedotin - Drug Profile
budesonide - Drug Profile
cannabidiol - Drug Profile
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile
Cell Therapy for Graft Versus Host Disease - Drug Profile
Cell Therapy for Graft Versus Host Disease - Drug Profile
Cell Therapy for Graft Versus Host Disease - Drug Profile
Cell Therapy for Graft versus Host Disease - Drug Profile
Cell Therapy for Graft Versus Host Disease - Drug Profile
Cell Therapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile
cenicriviroc mesylate - Drug Profile
CLBS-03 - Drug Profile
CRCBT-080004 - Drug Profile
cyclosporine IR + cyclosporine CR - Drug Profile
CYP-001 - Drug Profile
defibrotide - Drug Profile
Drugs for Acute and Chronic GVHD - Drug Profile
erismodegib - Drug Profile
F-652 - Drug Profile
Fc-Alpha-1 Antitrypsin - Drug Profile
FcAAT-2 - Drug Profile
FcAAT-3 - Drug Profile
Ha-7 - Drug Profile
ibrutinib - Drug Profile
ImmuneSafe - Drug Profile
Immunocellgram for Graft Versus Host Disease - Drug Profile
IMO-8400 - Drug Profile
inolimomab - Drug Profile
IT-603 - Drug Profile
IT-901 - Drug Profile
KD-025 - Drug Profile
KY-1005 - Drug Profile
MesoStem - Drug Profile
MGD-010 - Drug Profile
milatuzumab - Drug Profile
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
MSM-707 - Drug Profile
MultiStem - Drug Profile
natalizumab - Drug Profile
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile
panobinostat - Drug Profile
ponesimod - Drug Profile
Preimplantation Factor - Drug Profile
PRO-140 - Drug Profile
Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease - Drug Profile
Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile
remestemcel-L - Drug Profile
RGI-2001 - Drug Profile
RO-2959 - Drug Profile
RTU-009 - Drug Profile
Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile
Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
SP-12008 - Drug Profile
Substance X - Drug Profile
T-Guard - Drug Profile
TZ-101 - Drug Profile
Graft Versus Host Disease (GVHD) - Recent Pipeline Updates
Graft Versus Host Disease (GVHD) - Dormant Projects
Graft Versus Host Disease (GVHD) - Discontinued Products
Graft Versus Host Disease (GVHD) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Biogen, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by CytoDyn Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma B.V., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2015
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H2 2015
Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2015
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2015
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2015
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2015
Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2015
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015’, provides an overview of the Graft Versus Host Disease (GVHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;